A dual-targeting bispecific antibody and T-cell engager (BiTE) co-targeting both the human tumor-associated antigens (TAAs) cadherin-3 (CDH3; placental cadherin; P-cadherin) and mesothelin (MSLN) on tumor cells and CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities.

May 29, 2023 · In vitro, AMG 305 induces potent cytotoxicity against tumor cells co-expressing CDH3 and MSLN, with greatly attenuated activity against cells expressing only CDH3 or MSLN. In vivo, AMG 305 demonstrates dose-dependent antitumor …

The clinical trials on this list are studying anti-cdh3/msln bite antibody amg 305. All trials on the list are NCI-supported clinical trials, which are sponsored or otherwise financially supported by NCI.

May 11, 2023 · The agent induces potent cytotoxicity against tumor cells that co-express CDH3 and MSLN, which were selected as targets based on the co-expression seen in lung and other solid tumor types, but only rarely in normal tissue, she explained.

BiTE ® (bispecific T-cell engager) molecules exert antitumor activity by binding one arm to CD3 on cytotoxic T-cells and the other arm to a tumor-associated antigen. We generated a fully mouse cross-reactive mesothelin (MSLN)-targeted BiTE molecule that is genetically fused to a Fc-domain …

AMG 305 is a first dual-targeting BiTE (dBiTE™) molecule (CDH3-MSLN half-life extended [HLE] dBiTE™ AND dual targeting, HLE BiTE molecule) that targets the antigens P-cadherin (CDH3) and MSLN as well as CD3 on T-cells.

AMG 305, a dual targeting BiTE®molecule with selective activity for solid tumors that co-express CDH3 and MSLN (AACR 2023) - "AMG 305 was clinically well-tolerated in a nonclinical safety study in cynomolgus monkey.

Apr 19, 2024 · In this study, we used a unique avidity-driven in vitro screening approach to generate pCAD x CDH17 bispecific antibodies that selectively targets cells expressing both antigens over cells expressing only pCAD or only CDH17.

May 29, 2023 · AMG 305 relies on an avidity-based approach to engage T cells to preferentially kill CDH3+MSLN+ tumor cells, with limited activity against normal cells that express only one of the target...

Apr 17, 2023 · AMG-305, a first-in-class dual-targeting BiTE molecule with selectivity against CDH3+MSLN+ solid tumors. At the ongoing AACR meeting, Amgen Inc. provided details on the discovery and preclinical characterization of AMG-305, a novel dual-targeting bispecific T-cell engager (BiTE) molecule, being developed as a potential new anticancer agent.